野芭蕉对经皮冠状动脉介入术CYP2C19基因中间代谢表型患者的疗效观察
Observation of the Therapeutic Effect of Wild Plantain on Patients with CYP2C19 Gene In-termediate Metabolic Phenotype during Percutaneous Coronary Intervention
DOI: 10.12677/ACM.2023.1392090, PDF,  被引量    科研立项经费支持
作者: 潘兴寿, 李天资:右江民族医学院附属医院心血管内科,广西 百色;李近都:广西医科大学附属肿瘤医院肝胆外科,广西 南宁;梁 烨:右江民族医学院附属医院教学部,广西 百色;蔡 键, 班青丽, 卢国康, 王秋燕, 韦 唯:右江民族医学院研究生学院,广西 百色;邹才华*:右江民族医学院附属医院腺体外科,广西 百色
关键词: 急性冠状动脉综合征经皮冠状动脉介入治疗抗血小板抵抗CYP2C19基因野芭蕉
摘要: 目的:探讨野芭蕉对CYP2C19基因中间代谢表型(IMP)患者的疗效及其机制。方法:选90例IMP患者,随机分为中药组和西药组,中药组用常量氯吡格雷 + 石斛野蕉处方治疗,西药组用双倍量氯吡格雷治疗,连用180 ± 10 D。比较两组患者血小板最大聚集率(MPAR)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FBG)、血尿酸(AU)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDLC)、低密度脂蛋白胆固醇(LDLC)、极低密度脂蛋白胆固醇(vLDLC)、甘油三酯(TG)、再梗和出血水平。结果:中药组PMAR有效率高于西药组(P < 0.01)。中药组SBP、DBP、FBG、AU、TC、vLDLC和TG水平低于西药组(P < 0.01或P < 0.05)。随访 ≥ 6个月,中药组患者发生再梗1例,占2.2%,西药组发生再梗5例,占11.1%,发生出2例,占4.4%。两组患者再梗率、出血率比较,差异没有统计学意义(P > 0.05)。结论:野芭蕉可有效缓解中间代谢型患者血小板紊乱情况,减少经皮冠状动脉介入治疗患者出血和再梗死的发生率,其作用机制与降低患者的血压、血脂、血糖和血尿酸水平有关。
Abstract: Objective: To investigate the therapeutic effect and mechanism of wild plantain on patients with intermediate metabolic phenotype (IMP) of CYP2C19 gene. Methods: 90 patients with IMP were randomly divided into two groups: the Chinese Medicine Group and the Western medicine group. The Chinese medicine group was treated with clopidogrel and wild plantain of Dendrobium, while the western medicine group was treated with clopidogrel of double dosage for 180 ± 10 days. Max-imum platelet aggregation rate (MPAR), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), serum uric acid (AU), total cholesterol (TC), high-density lipo-protein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), low-density lipoprotein cho-lesterol (VLDLC), triglyceride cholesterol (TG), reinfarction and bleeding were compared between the two groups. Results: The effective rate of PMAR in Chinese medicine group was higher than that in Western medicine group (P < 0.01). The levels of SBP, DBP, FBG, Au, Tc, VLDLC and TG in the Chi-nese medicine group were lower than those in the Western Medicine Group (P < 0.01 or P < 0.05). After 6 months follow-up, 1 case (2.2%) in Chinese medicine group, 5 cases (11.1%) in Western medicine group and 2 cases (4.4%) in Western medicine group had reinfarction. There was no sig-nificant difference in reinfarction rate and bleeding rate between the two groups (P > 0.05). Conclu-sion: Wild plantain can effectively alleviate the platelet disorder in patients with intermediate me-tabolism type and reduce the incidence of bleeding and reinfarction in patients undergoing percu-taneous coronary intervention, the mechanism of action is related to the lowering of blood pressure, blood lipid, blood glucose and blood uric acid.
文章引用:潘兴寿, 李近都, 梁烨, 蔡键, 班青丽, 卢国康, 王秋燕, 韦唯, 李天资, 邹才华. 野芭蕉对经皮冠状动脉介入术CYP2C19基因中间代谢表型患者的疗效观察[J]. 临床医学进展, 2023, 13(9): 14935-14943. https://doi.org/10.12677/ACM.2023.1392090

参考文献

[1] Akbari, T. and Al-Lamee, R. (2022) Percutaneous Coronary Intervention in Multi-Vessel Disease. Cardiovascular Re-vascularization Medicine, 44, 80-91. [Google Scholar] [CrossRef] [PubMed]
[2] Vural Doğru, B., ŞenuzunAykar, F., Yıldırım, Y., et al. (2021) The Effect of Foot Reflexology Applied before Coronary Angiography and Percutaneous Transluminal Coronary Angioplasty on Anxiety, Stress, and Cortisol Levels of Individuals A Randomized Controlled Trial. The Journal of Cardiovascular Nursing, 36, 461-469. [Google Scholar] [CrossRef
[3] Essa, H., Sankaranarayanan, R. and Walker, L. (2022) Triple Antithrombotic Therapy and Dual Therapy—What Is the Evidence Base? British Journal of Clinical Pharmacology, 88, 3009-3012. [Google Scholar] [CrossRef] [PubMed]
[4] Costa, G.F., Costa, M., Gonçalves, L. and Teixeira, R. (2021) Antiplatelet Therapy after Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis. European Journal of Cardio-Thoracic Surgery, 60, 1022-1029. [Google Scholar] [CrossRef] [PubMed]
[5] Topçuoglu, M.A., Arsava, E.M. and Ay, H. (2011) Antiplatelet Re-sistance in Stroke. Expert Review of Neurotherapeutics, 11, 251-263. [Google Scholar] [CrossRef] [PubMed]
[6] Machalz, D., Pach, S., Bermudez, M., Bureik, M. and Wolber, G. (2021) Structural Insights into Understudied Human Cytochrome P450 Enzymes. Drug Discovery Today, 26, 2456-2464. [Google Scholar] [CrossRef] [PubMed]
[7] 陆荣臻, 黄江南, 潘兴寿, 等. 不同降压模式在老年高血压合并冠心病患者PCI术后的应用效果研究[J]. 天津医药, 2023, 51(3): 277-281.
[8] Ellithi, M., Baye, J. and Wilke, R.A. (2020) CYP2C19 Genotype-Guided Antiplatelet Therapy: Promises and Pitfalls. Pharmacogenomics, 21, 889-897. [Google Scholar] [CrossRef] [PubMed]
[9] 蓝家富, 梁烨, 李近都, 等. 高血压合并原发性醛固酮增多症患者肾上腺超声声像回声强度与临床特征的关系[J]. 广西医学, 2022, 44(2): 149-153.
[10] Joob, B. and Wiwanitkit, V. (2020) CYP2C19*2 Polymorphism and Clopidogrel Resistance. Archivos de Cardiología de México, 90, 505. [Google Scholar] [CrossRef
[11] 李天资, 梁烨, 陆高翔, 等. 野芭蕉治疗高血压颈动脉斑块阳性患者疗效机制的临床研究[J]. 时珍国医国药, 2012, 23(9): 2259-2260.
[12] 中华医学会心血管病学分会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中华心血管病杂志, 2019, 47(10): 766-783.
[13] 何思陆, 李天资. FXYD5在高血压病动脉粥样硬化中调控机制的研究进展[J]. 中西医结合心脑血管病杂志, 2015, 13(15): 1730-1732.
[14] 潘兴寿, 梁烨, 李天资, 等. 野芭蕉辅助治疗高血压伴稳定劳力型心绞痛PCI术后患者炎症反应疗效观察[J]. 时珍国医国药, 2014, 25(9): 2171-2173.
[15] 唐汉庆, 赵玉峰, 李天资, 等. 铁皮石斛对冠心病模型家兔心功能和血管变化的影响[J]. 世界科学技术-中医药现代化, 2015, 17(4): 856-860.
[16] 李鸿翔, 李近都, 梁烨, 等. 高血压颈动脉斑块阳性患者miR-375表达检测[J]. 右江医学, 2015, 43(1):16-19.
[17] Liang, Y., Zou, C., Li, J., Li, S. and Li, T. (2019) Research Progress of Medicinal Secondary Metabolites and Gene Cloning of Den-drobium Officinale. Medicinal Plant, 10, 16-23.
[18] Tang, H., Zheng, J., Li, T., et al. (2016) Effect of Combined Med-icated Thread Moxibustion Plus Needle Picking Therapy of Zhuang Nationality Medicine on Antioxidant Levels in a Rat Model of Sciatica. Journal of Traditional Chinese Medicine, 36, 784-788. [Google Scholar] [CrossRef
[19] Cho, C.-K., Byeon, J.-Y., Kang, P., et al. (2023) Effects of CYP2C19 Genetic Polymorphism on the Pharmacokinetics of Tolperisone in Healthy Subjects. Archives of Pharmacal Research, 46, 111-116. [Google Scholar] [CrossRef] [PubMed]
[20] Kow, C.S., Zaihan, A.F. and Hasan, S.S. (2021) CYP2C19 Genotype-Guided Antiplatelet Therapy among Asian Patients with Ischaemic Stroke. Clinical Drug Investigation, 41, 115-116. [Google Scholar] [CrossRef] [PubMed]
[21] Alkattan, A., Almutairi, Y., Alsalameen, E., Alkhalifah, A. and Alghanim, F. (2021) The CYP2C19 Genotypes and Its Effect on Clopidogrel as an Anti-Platelet Drug among the Arab Population. Indian Journal of Pharmacology, 53, 85-87. [Google Scholar] [CrossRef
[22] 韦宝敏, 潘兴寿, 李天资, 等. H型高血压患者MTHFR C677T基因多态性及其与血压、HCY水平的关系[J]. 检验医学与临床, 2021, 18(7): 889-892.
[23] Zastrozhin, M.S., Skryabin, V., Rwere, F., et al. (2022) Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder. Psychopharmacology Bulletin, 52, 8-19.
[24] Ball, S.T.E., Taylor, R. and McCollum, C.N. (2020) Resistance to An-tiplatelet Therapy Is Associated with Symptoms of Cerebral Ischemia in Carotid Artery Disease. Vascular and Endovas-cular Surgery, 54, 712-717. [Google Scholar] [CrossRef] [PubMed]
[25] 言纬, 潘兴寿, 李近都, 等. 心电射频消融术在急性冠状动脉综合征伴频发性室性早搏患者复律治疗中的应用观察[J]. 山东医药, 2023, 63(5): 23-26.
[26] 梁烨, 李天资, 陆高翔, 等. 野芭蕉通络汤对改善高血压患者氧化应激功能紊乱疗效观察[J]. 中华中医药杂志, 2012, 27(7): 1967-1969.
[27] Wiśniewski, A. (2021) Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention. Medicina, 57, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
[28] Monteyne, T., Heireman, L., Hemelsoet, D., van Schaik, R.H.N. and Devreese, K.M.J. (2021) Is Monitoring of Antiplatelet Therapy by Light Transmission Aggregometry Dependent on Instrument and Reagent Used? International Journal of Laboratory Hematology, 43, 786-794. [Google Scholar] [CrossRef] [PubMed]
[29] 蓝家富, 李近都, 李天资. 甲硫氨酸腺苷转移酶基因与临床研究进展[J], 临床医学进展, 2020, 10(3): 165-171.
[30] 潘兴寿, 赖腾芳, 李近都, 等. 石斛多糖抑制自发性高血压大鼠RAGE mRNA有效剂量的循证医学观察[J]. 中华中医药杂志, 2019, 34(7): 3026-3030.
[31] 赖腾芳, 李近都, 邹才华, 等. 石斛多糖抑制自发性高血压大鼠晚期糖基化终产物受体mRNA的有效剂量观察[J]. 广东医学, 2020, 41(2): 109-112.
[32] 曾德创, 邹才华, 李近都, 等. 石斛治疗血栓闭塞性脉管炎患者炎症细胞因子变化的观察[J]. 中国医药科学, 2016, 6(21): 9-12, 17.
[33] 何思陆, 梁烨, 陆高翔, 等. 铁皮石斛处方辅助治疗肺结核效果的临床观察[J]. 中国医药科学, 2015, 5(10): 7-9.
[34] 何思陆, 陆高翔, 梁烨, 等. 富马酸比索洛尔联合野芭蕉治疗腔隙性脑梗塞疗效观察[J]. 山东大学学报(医学版), 2014, 52(z1): 40-42.
[35] Calcagno, S., Di Pietro, R., Biondi-Zoccai, G. and Versaci, F. (2020) Do We Really Need Routine CYP2C19 Genotyping. JACC: Cardiovascular Interventions, 13, 1134-1135. [Google Scholar] [CrossRef] [PubMed]
[36] 陆积新, 李近都, 潘兴寿, 等. 石斛多糖对SHR晚期糖基化终产物代谢变化及其与炎症因子的关系[J]. 中国医药科学, 2020, 10(1): 9-13.
[37] 何思陆, 陆高翔, 梁烨, 等. 铁皮石斛对急性有机磷农药中毒患者解毒及其抗氧化的疗效观察[J]. 中药药理与临床, 2015, 31(2): 98-99.